JP2019506401A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506401A5 JP2019506401A5 JP2018538219A JP2018538219A JP2019506401A5 JP 2019506401 A5 JP2019506401 A5 JP 2019506401A5 JP 2018538219 A JP2018538219 A JP 2018538219A JP 2018538219 A JP2018538219 A JP 2018538219A JP 2019506401 A5 JP2019506401 A5 JP 2019506401A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- pharmaceutically acceptable
- acceptable salt
- pilocarpine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 47
- 150000003839 salts Chemical class 0.000 claims 26
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical group C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 claims 17
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 claims 17
- 229960001416 pilocarpine Drugs 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 13
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical group C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims 12
- 208000008454 Hyperhidrosis Diseases 0.000 claims 12
- 229960005434 oxybutynin Drugs 0.000 claims 12
- 230000037315 hyperhidrosis Effects 0.000 claims 11
- 230000035922 thirst Effects 0.000 claims 6
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000003149 muscarinic antagonist Substances 0.000 claims 4
- 230000036470 plasma concentration Effects 0.000 claims 4
- 239000001856 Ethyl cellulose Substances 0.000 claims 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 3
- 239000011247 coating layer Substances 0.000 claims 3
- 229920001249 ethyl cellulose Polymers 0.000 claims 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
- 239000010410 layer Substances 0.000 claims 3
- 230000000007 visual effect Effects 0.000 claims 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 239000011324 bead Substances 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 239000008185 minitablet Substances 0.000 claims 2
- 239000000472 muscarinic agonist Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 239000004368 Modified starch Substances 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 210000001099 axilla Anatomy 0.000 claims 1
- 230000036617 axillary hyperhidrosis Effects 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920001688 coating polymer Polymers 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000037391 generalized hyperhidrosis Effects 0.000 claims 1
- 208000012155 generalized hyperhidrosis Diseases 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- 230000037392 palmar hyperhidrosis Effects 0.000 claims 1
- 230000036563 plantar hyperhidrosis Effects 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 150000004804 polysaccharides Chemical class 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2016/014150 WO2017127073A1 (en) | 2016-01-20 | 2016-01-20 | Methods and compositions for treating hyperhidrosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506401A JP2019506401A (ja) | 2019-03-07 |
| JP2019506401A5 true JP2019506401A5 (enExample) | 2019-04-18 |
| JP6841834B2 JP6841834B2 (ja) | 2021-03-10 |
Family
ID=59314209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018538219A Active JP6841834B2 (ja) | 2016-01-20 | 2016-01-20 | 多汗症の処置のための方法および組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10328057B2 (enExample) |
| EP (1) | EP3405191B1 (enExample) |
| JP (1) | JP6841834B2 (enExample) |
| KR (2) | KR102495757B1 (enExample) |
| CN (1) | CN108697688A (enExample) |
| AU (2) | AU2016388308B2 (enExample) |
| BR (1) | BR112018014661A2 (enExample) |
| CA (1) | CA3011683C (enExample) |
| DK (1) | DK3405191T3 (enExample) |
| HK (1) | HK1258825A1 (enExample) |
| MX (1) | MX394356B (enExample) |
| RU (1) | RU2718906C2 (enExample) |
| TW (2) | TWI810150B (enExample) |
| WO (1) | WO2017127073A1 (enExample) |
| ZA (1) | ZA201805490B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3061821B1 (en) | 2009-07-22 | 2019-07-10 | Puretech Health LLC | Compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| SG174658A1 (en) | 2010-04-01 | 2011-10-28 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
| JP6841834B2 (ja) | 2016-01-20 | 2021-03-10 | テラヴィダ, インコーポレイテッドTheraVida, Inc. | 多汗症の処置のための方法および組成物 |
| CA3180743A1 (en) | 2018-09-28 | 2020-04-02 | Karuna Therapeutics, Inc. | Composition comprising xanomeline and trospium for treating disorders ameliorated by muscarinic receptor activation |
| KR20220027943A (ko) | 2019-07-05 | 2022-03-08 | 스웨디쉬 매치 노스 유럽 에이비 | 니코틴 함유 입자를 포함하는 충전 재료를 포함하는 경구 파우치형 니코틴 제품 |
| EP4356759A3 (en) | 2019-11-20 | 2024-07-03 | Swedish Match North Europe AB | An oral pouched nicotine product including a filling material comprising nicotine particles |
| EP3967311A1 (en) * | 2020-09-11 | 2022-03-16 | Astellas Pharma Inc. | Compounds for use in the treatment of dry mouth |
| PL4018849T3 (pl) | 2020-12-22 | 2025-02-10 | Swedish Match North Europe Ab | Wyrób w saszetkach do użytku doustnego |
| EP4018847B1 (en) | 2020-12-22 | 2024-09-18 | Swedish Match North Europe AB | A pouched product for oral use |
| EP4018848B1 (en) | 2020-12-22 | 2024-09-18 | Swedish Match North Europe AB | A pouched product for oral use comprising a liquid permeable cover material and a filling material |
| AU2022326451A1 (en) * | 2021-08-11 | 2024-02-08 | Theravida, Inc. | Pharmaceutical compositions and methods for treating hyperhidrosis |
| WO2024162929A1 (en) * | 2023-01-27 | 2024-08-08 | Ardi Farma Ilac Pazarlama Ticaret Limited Sirketi | A controlled release formulation of propiverine |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4209505A (en) | 1979-04-03 | 1980-06-24 | Mikhail Adib R | Pilocarpine mouthwash for dry mouth relief |
| US4302440B1 (en) * | 1980-07-31 | 1986-08-05 | Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof | |
| SE450087B (sv) | 1985-10-11 | 1987-06-09 | Haessle Ab | Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial |
| PH30929A (en) | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
| US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| WO1995022962A1 (en) | 1994-02-23 | 1995-08-31 | Bm Research A/S | Controlled release composition |
| US5674895A (en) | 1995-05-22 | 1997-10-07 | Alza Corporation | Dosage form comprising oxybutynin |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO1998030208A1 (en) | 1997-01-10 | 1998-07-16 | Abbott Laboratories | Tablet for the controlled release of active agents |
| AU734248B2 (en) * | 1997-03-26 | 2001-06-07 | Janssen Pharmaceutica N.V. | Pellets having a core coated with an antifungal and a polymer |
| SI1041987T1 (sl) | 1997-12-22 | 2006-10-31 | Euro Celtique Sa | Farmacevtska oralna dozirna oblika, ki obsega kombinacijo opioidnega agonista in naltreksona |
| AU755790B2 (en) | 1997-12-22 | 2002-12-19 | Euro-Celtique S.A. | A method of preventing abuse of opioid dosage forms |
| US6482837B1 (en) | 1998-04-24 | 2002-11-19 | University Of Rochester | Antimuscarinic compounds and methods for treatment of bladder diseases |
| US5997905A (en) | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
| WO2000024423A1 (en) | 1998-10-26 | 2000-05-04 | Tanabe Seiyaku Co., Ltd. | Sustained-release particles |
| FR2795962B1 (fr) | 1999-07-08 | 2003-05-09 | Prographarm Laboratoires | Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif |
| JP2003509439A (ja) | 1999-09-14 | 2003-03-11 | スミスクライン・ビーチャム・コーポレイション | 水性コーティングされたビーズレットの製法 |
| AU784104B2 (en) | 1999-11-11 | 2006-02-02 | Pfizer Health Ab | Pharmaceutical formulation containing tolterodine and its use |
| WO2001054728A1 (fr) | 2000-01-28 | 2001-08-02 | Asahi Kasei Kabushiki Kaisha | NOUVEAUX REMEDES ET UTILISATION D'UN AGONISTE β3 |
| US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| US6419954B1 (en) | 2000-05-19 | 2002-07-16 | Yamanouchi Pharmaceutical Co., Ltd. | Tablets and methods for modified release of hydrophilic and other active agents |
| US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| JP2005521706A (ja) | 2002-03-29 | 2005-07-21 | アルザ・コーポレーシヨン | 体積効果的放出制御製剤 |
| FR2842736B1 (fr) | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
| FR2842735B1 (fr) | 2002-07-26 | 2006-01-06 | Flamel Tech Sa | Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os |
| US9107804B2 (en) | 2002-12-10 | 2015-08-18 | Nortec Development Associates, Inc. | Method of preparing biologically active formulations |
| EP1635795A1 (en) | 2003-05-30 | 2006-03-22 | Ranbaxy Laboratories, Ltd. | Controlled release pharmaceutical compositions of tolterodine and processes for their preparation |
| EP1651192A1 (en) | 2003-08-06 | 2006-05-03 | Nirmal Mulye | Pharmaceutical composition containing water soluble drug |
| DE602004030931D1 (enExample) | 2003-11-04 | 2011-02-17 | Supernus Pharmaceuticals Inc | |
| RU2382637C2 (ru) | 2004-04-30 | 2010-02-27 | Астеллас Фарма Инк. | Фармацевтическая композиция для перорального введения в форме частиц с рассчитанным временем высвобождения и быстро распадающиеся таблетки, содержащие указанную композицию |
| WO2005115340A1 (en) | 2004-05-19 | 2005-12-08 | Glatt Air Techniques, Inc. | Micropellet containing pellets and method of preparing such pellets |
| WO2005123042A1 (en) | 2004-06-10 | 2005-12-29 | Glatt Air Techniques, Inc. | Controlled release pharmaceutical formulation |
| JP2008516893A (ja) | 2004-08-27 | 2008-05-22 | スフェリックス，インク． | 多層錠剤および生体接着性剤形 |
| EP1629834A1 (en) | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Sustained release pharmaceutical composition of tolterodine |
| WO2006132196A1 (ja) | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | β３作動薬を含有する新規な医薬 |
| CN101287462A (zh) | 2005-09-02 | 2008-10-15 | 塞拉维达公司 | 治疗疾病的疗法 |
| WO2007029087A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Controlled release multiple unit formulations |
| US20070077300A1 (en) | 2005-09-30 | 2007-04-05 | Wynn David W | Oral compositions containing a salivation inducing agent |
| EP1951186A4 (en) * | 2005-10-19 | 2009-11-04 | Menni Menashe Zinger | METHODS FOR TREATING HYPERHIDROSIS |
| CA2680680A1 (en) | 2007-03-29 | 2009-02-19 | Panacea Biotec Limited | Modified dosage forms of tacrolimus |
| US7563508B2 (en) | 2007-05-30 | 2009-07-21 | Chung Shan Institute Of Science And Technology, Armaments Bureau, M.N.D. | Diffusion beads with core-shell structure |
| US20090017111A1 (en) | 2007-07-03 | 2009-01-15 | Van Den Heuvel Dennie J M | Tolterodine bead |
| US8110226B2 (en) | 2007-07-20 | 2012-02-07 | Mylan Pharmaceuticals Inc. | Drug formulations having inert sealed cores |
| EP2175843B1 (en) | 2007-08-08 | 2014-10-08 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
| US9561015B2 (en) * | 2007-08-24 | 2017-02-07 | General Electric Company | Method and apparatus for voice recording with ultrasound imaging |
| BRPI0817275A2 (pt) | 2007-09-28 | 2015-06-16 | Novartis Ag | Combinação farmacêutica de alisquireno e valsartana |
| JP2011502140A (ja) | 2007-10-29 | 2011-01-20 | ルピン・リミテッド | トルテロジンの制御放出型医薬組成物 |
| US20090192228A1 (en) | 2008-01-28 | 2009-07-30 | Actavis Group Ptc Ehf | Controlled-Release Tolterodine Compositions and Methods |
| US20090247628A1 (en) * | 2008-03-25 | 2009-10-01 | Auspex Pharmaceuticals, Inc. | Substituted phenylcyclohexylglycolates |
| SG174658A1 (en) * | 2010-04-01 | 2011-10-28 | Theravida Inc | Pharmaceutical formulations for the treatment of overactive bladder |
| WO2011123815A1 (en) | 2010-04-01 | 2011-10-06 | Theravida, Inc. | Methods of improving quality of sleep |
| US20120289560A1 (en) | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder |
| SG194809A1 (en) | 2011-05-10 | 2013-12-30 | Theravida Inc | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder |
| US20140037713A1 (en) * | 2012-08-03 | 2014-02-06 | Antares Pharma Ipl, Ag | Transdermal compositions for anti-cholinergic agents |
| US20140105976A1 (en) | 2012-10-11 | 2014-04-17 | Theravida, Inc. | Pharmaceutical formulations of pilocarpine |
| JP6841834B2 (ja) | 2016-01-20 | 2021-03-10 | テラヴィダ, インコーポレイテッドTheraVida, Inc. | 多汗症の処置のための方法および組成物 |
-
2016
- 2016-01-20 JP JP2018538219A patent/JP6841834B2/ja active Active
- 2016-01-20 BR BR112018014661A patent/BR112018014661A2/pt not_active Application Discontinuation
- 2016-01-20 KR KR1020187023444A patent/KR102495757B1/ko active Active
- 2016-01-20 RU RU2018128047A patent/RU2718906C2/ru active
- 2016-01-20 AU AU2016388308A patent/AU2016388308B2/en active Active
- 2016-01-20 HK HK19101228.1A patent/HK1258825A1/zh unknown
- 2016-01-20 CA CA3011683A patent/CA3011683C/en active Active
- 2016-01-20 DK DK16886713.3T patent/DK3405191T3/da active
- 2016-01-20 EP EP16886713.3A patent/EP3405191B1/en active Active
- 2016-01-20 CN CN201680082300.6A patent/CN108697688A/zh active Pending
- 2016-01-20 MX MX2018008694A patent/MX394356B/es unknown
- 2016-01-20 WO PCT/US2016/014150 patent/WO2017127073A1/en not_active Ceased
- 2016-01-20 KR KR1020237003623A patent/KR102600541B1/ko active Active
-
2017
- 2017-01-12 TW TW106101040A patent/TWI810150B/zh active
- 2017-01-12 TW TW112107474A patent/TW202341976A/zh unknown
- 2017-03-10 US US15/456,414 patent/US10328057B2/en active Active
-
2018
- 2018-08-16 ZA ZA201805490A patent/ZA201805490B/en unknown
-
2019
- 2019-05-03 US US16/403,115 patent/US10610519B2/en active Active
-
2020
- 2020-02-21 US US16/797,863 patent/US11185533B2/en active Active
-
2021
- 2021-11-01 US US17/453,101 patent/US11779569B2/en active Active
-
2022
- 2022-07-19 AU AU2022206709A patent/AU2022206709A1/en not_active Abandoned